<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976440</url>
  </required_header>
  <id_info>
    <org_study_id>CRRT/SLED-RCA protocol</org_study_id>
    <nct_id>NCT03976440</nct_id>
  </id_info>
  <brief_title>Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study</brief_title>
  <official_title>Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study are: 1) To evaluate the occurrence of acid-base alterations and the
      incidence of hypophosphatemia during different modalities of Renal Replacement Terapy (RRT)
      in critically ill patients [CVVH, CVVHDF and SLED (Sustained Low-Efficiency Dialysis)] by
      using a simplified Regional Citrate Anticoagulation (RCA) protocol combined with the adoption
      of a phosphate-containing solution as dialysate and/or replacement fluid; 2) To optimize the
      infusion rates of different solutions adopted, including citrate, in order to obtain an
      appropriate electrolyte and buffer supply. The final aim of this approach will be to reduce
      the need for frequent monitoring of acid-base status and electrolytes (with special regard to
      ionized calcium levels), and to avoid the need for frequent adjustments of RCA-RRT parameters
      (infusion rate of different solutions, electrolytes supplementation in the course of RRT).
      This approach could allow to simplify anticoagulation protocols with citrate, in order to
      minimize potential concerns hampering a wider diffusion of RCA in daily practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The need for continuous anticoagulation represents a potential drawback of RRT modalities.
      KDIGO 2012 guidelines on acute kidney injury (AKI) suggest the adoption of RCA as first
      choice anticoagulation modality for continuous RRT (CRRT) in patients without
      contraindications for citrate. Citrate has been also introduced as anticoagulant for SLED and
      its use in the context of a mainly diffusive prolonged intermittent modality has been shown
      to represent an easy and safe method to maintain the extracorporeal circuit when concentrated
      citrate solutions, such as ACD-A are used. Hypophosphatemia is a known issue of RRT, and has
      been reported in up to 50-80% of cases when standard RRT solutions are used, especially in
      continuous/prolonged intermitted modalities when high RRT doses are delivered. RRT-related
      phosphate depletion should be avoided in critically ill patients due to the relevant
      hypophosphatemia-associated complications in this clinical setting. The adoption of
      phosphate-containing CRRT solutions could reduce the incidence of hypophosphatemia and
      minimize the need for parenteral phosphorus supplementation.The adoption of a commercially
      available phosphate-containing CRRT solution, in the setting of RCA-RRT may allow to meet the
      double target of minimizing RRT-induced hypophosphatemia and ensuring an adequate circuit
      life, also avoiding electrolyte and acid-base derangements.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hypophosphatemia</measure>
    <time_frame>72 hours</time_frame>
    <description>Occurrence of hypophosphatemia during the first 72 hours of continuous renal replacement therapy (CRRT) or sustained low-efficiency dialysis (SLED)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acid-base derangements</measure>
    <time_frame>72 hours</time_frame>
    <description>Occurrence of acid-base derangements during CRRT and SLED using a simplified RCA protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of RCA-RRT parameters</measure>
    <time_frame>72 hours</time_frame>
    <description>Evaluation of the need for variations of RCA-RRT dialysis parameters from initial RRT settings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variations of RCA-RRT solutions</measure>
    <time_frame>72 hours</time_frame>
    <description>Evaluation of the need for variations in RRT solutions flow rate rom initial RRT settings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypomagnesemia</measure>
    <time_frame>72 hours</time_frame>
    <description>Occurrence of hypomagnesemia during the first 72 hours of CRRT or SLED</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of RCA</measure>
    <time_frame>72 hours</time_frame>
    <description>Efficacy of RCA in terms of circuit lifetime and filter efficiency</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Renal Failure</condition>
  <condition>Dialysis Related Complication</condition>
  <condition>Hypophosphatemia</condition>
  <condition>Hypomagnesemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Renal Replacement Therapy (RRT) start</intervention_name>
    <description>At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples to determine the citrate concentration in course of renal replacement therapy
      (RRT) in the setting of regional citrate anticoagulation (RCA)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients aged &gt;=18 years with severe acute kidney injury (AKI) or end stage
        renal disease (ESRD) requiring renal replacement therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  critically ill patients requiring continuous or prolonged intermittent renal
             replacement therapy for severe acute kidney injury (AKI)

          -  critically ill patients requiring continuous or prolonged intermittent renal
             replacement therapy for end stage renal disease (ESRD)

        Exclusion Criteria:

          -  age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Parma - UO Nefrologia AOU</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf</url>
    <description>KDIGO Clinical Practice Guideline for Acute Kidney Injury</description>
  </link>
  <results_reference>
    <citation>Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol. 2006 Jan;2(1):32-9. Review.</citation>
    <PMID>16932387</PMID>
  </results_reference>
  <results_reference>
    <citation>VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008 Jul 3;359(1):7-20. doi: 10.1056/NEJMoa0802639. Epub 2008 May 20. Erratum in: N Engl J Med. 2009 Dec 10;361(24):2391.</citation>
    <PMID>18492867</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F, Pozzato M, Canepari G, Vitale C, Bermond F, Sacco C, Amore A, Manes M, Navino C; Piedmont and Aosta Valley Section of Italian Society of Nephrology. Renal replacement therapy in intensive care units: a survey of nephrological practice in northwest Italy. J Nephrol. 2011 Mar-Apr;24(2):165-76.</citation>
    <PMID>20586025</PMID>
  </results_reference>
  <results_reference>
    <citation>Marshall MR, Golper TA. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial. 2011 Mar-Apr;24(2):142-8. doi: 10.1111/j.1525-139X.2011.00829.x.</citation>
    <PMID>21517979</PMID>
  </results_reference>
  <results_reference>
    <citation>Marshall MR, Creamer JM, Foster M, Ma TM, Mann SL, Fiaccadori E, Maggiore U, Richards B, Wilson VL, Williams AB, Rankin AP. Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant. 2011 Jul;26(7):2169-75. doi: 10.1093/ndt/gfq694. Epub 2010 Nov 12.</citation>
    <PMID>21075821</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwenger V, Weigand MA, Hoffmann O, Dikow R, Kihm LP, Seckinger J, Miftari N, Schaier M, Hofer S, Haar C, Nawroth PP, Zeier M, Martin E, Morath C. Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care. 2012 Jul 27;16(4):R140. doi: 10.1186/cc11445. Erratum in: Crit Care. 2012;16(5):451.</citation>
    <PMID>22839577</PMID>
  </results_reference>
  <results_reference>
    <citation>Fieghen HE, Friedrich JO, Burns KE, Nisenbaum R, Adhikari NK, Hladunewich MA, Lapinsky SE, Richardson RM, Wald R; University of Toronto Acute Kidney Injury Research Group. The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol. 2010 Nov 25;11:32. doi: 10.1186/1471-2369-11-32.</citation>
    <PMID>21106112</PMID>
  </results_reference>
  <results_reference>
    <citation>Kron J, Kron S, Wenkel R, Schuhmacher HU, Thieme U, Leimbach T, Kern H, Neumayer HH, Slowinski T. Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure. Nephrol Dial Transplant. 2012 Jan;27(1):146-52. doi: 10.1093/ndt/gfr269. Epub 2011 May 28.</citation>
    <PMID>21622989</PMID>
  </results_reference>
  <results_reference>
    <citation>Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis. 2004 Feb;43(2):342-9.</citation>
    <PMID>14750100</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiaccadori E, Maggiore U, Parenti E, Giacosa R, Picetti E, Rotelli C, Tagliavini D, Cabassi A. Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant. 2007 Feb;22(2):529-37. Epub 2006 Oct 28.</citation>
    <PMID>17071958</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiaccadori E, Regolisti G, Cademartiri C, Cabassi A, Picetti E, Barbagallo M, Gherli T, Castellano G, Morabito S, Maggiore U. Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. Clin J Am Soc Nephrol. 2013 Oct;8(10):1670-8. doi: 10.2215/CJN.00510113. Epub 2013 Aug 29.</citation>
    <PMID>23990164</PMID>
  </results_reference>
  <results_reference>
    <citation>Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2173-88. doi: 10.2215/CJN.01280214. Epub 2014 Jul 3. Review.</citation>
    <PMID>24993448</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A. Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney Int. 2001 Apr;59(4):1510-9.</citation>
    <PMID>11260415</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiaccadori E, Pistolesi V, Mariano F, Mancini E, Canepari G, Inguaggiato P, Pozzato M, Morabito S. Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group &quot;Renal Replacement Therapies in Critically Ill Patients&quot; of the Italian Society of Nephrology. J Nephrol. 2015 Apr;28(2):151-64. doi: 10.1007/s40620-014-0160-2. Epub 2015 Jan 14. Review. Erratum in: J Nephrol. 2015 Apr;28(2):255.</citation>
    <PMID>25585821</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012 Aug 25;380(9843):756-66. doi: 10.1016/S0140-6736(11)61454-2. Epub 2012 May 21. Review.</citation>
    <PMID>22617274</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, Goldstein SL, Cerdá J, Chawla LS. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018 Oct;14(10):607-625. doi: 10.1038/s41581-018-0052-0. Review.</citation>
    <PMID>30135570</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS. Community-based incidence of acute renal failure. Kidney Int. 2007 Jul;72(2):208-12. Epub 2007 May 16.</citation>
    <PMID>17507907</PMID>
  </results_reference>
  <results_reference>
    <citation>Bagshaw SM, George C, Bellomo R; ANZICS Database Management Committee. Early acute kidney injury and sepsis: a multicentre evaluation. Crit Care. 2008;12(2):R47. doi: 10.1186/cc6863. Epub 2008 Apr 10.</citation>
    <PMID>18402655</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73. Epub 2006 May 12.</citation>
    <PMID>16696865</PMID>
  </results_reference>
  <results_reference>
    <citation>Morabito S, Pistolesi V, Cibelli L, Pierucci A. [Continuous renal replacement therapies (CRRT) will remain the most widely adopted dialysis modality in the critically ill]. G Ital Nefrol. 2009 Jan-Feb;26(1):13-21. Italian.</citation>
    <PMID>19255959</PMID>
  </results_reference>
  <results_reference>
    <citation>Brophy PD, Somers MJ, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, Bunchman TE, Goldstein SL. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant. 2005 Jul;20(7):1416-21. Epub 2005 Apr 26.</citation>
    <PMID>15855212</PMID>
  </results_reference>
  <results_reference>
    <citation>Oudemans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006 Feb;32(2):188-202. doi: 10.1007/s00134-005-0044-y. Epub 2006 Feb 2. Review.</citation>
    <PMID>16453140</PMID>
  </results_reference>
  <results_reference>
    <citation>Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial. 2009 Mar-Apr;22(2):141-5. doi: 10.1111/j.1525-139X.2008.00545.x. Review.</citation>
    <PMID>19426417</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F. [Citrate: a different mental approach to extracorporeal circuit anticoagulation]. G Ital Nefrol. 2012 Jan-Feb;29(1):27-32. Italian.</citation>
    <PMID>22388903</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F, Triolo G. [Anticoagulation of extracorporeal circuit in critically ill patients]. G Ital Nefrol. 2007 Jan-Feb;24(1):34-42. Italian.</citation>
    <PMID>17342691</PMID>
  </results_reference>
  <results_reference>
    <citation>Oudemans-van Straaten HM. Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif. 2010;29(2):191-6. doi: 10.1159/000245646. Epub 2010 Jan 8. Review.</citation>
    <PMID>20093826</PMID>
  </results_reference>
  <results_reference>
    <citation>Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009 Dec;2(6):439-47. doi: 10.1093/ndtplus/sfp136. Epub 2009 Sep 25.</citation>
    <PMID>25949376</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F, Tedeschi L, Morselli M, Stella M, Triolo G. Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients. Intensive Care Med. 2010 Oct;36(10):1735-43. doi: 10.1007/s00134-010-1909-2. Epub 2010 May 18.</citation>
    <PMID>20480135</PMID>
  </results_reference>
  <results_reference>
    <citation>Chadha V, Garg U, Warady BA, Alon US. Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol. 2002 Oct;17(10):819-24. Epub 2002 Sep 7.</citation>
    <PMID>12376810</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F, Tetta C, Stella M, Biolino P, Miletto A, Triolo G. Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood Purif. 2004;22(3):313-9.</citation>
    <PMID>15256798</PMID>
  </results_reference>
  <results_reference>
    <citation>Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2006 Nov;48(5):806-11.</citation>
    <PMID>17060000</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F, Morselli M, Bergamo D, Hollo Z, Scella S, Maio M, Tetta C, Dellavalle A, Stella M, Triolo G. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant. 2011 Dec;26(12):3882-8. doi: 10.1093/ndt/gfr106. Epub 2011 Mar 8.</citation>
    <PMID>21385861</PMID>
  </results_reference>
  <results_reference>
    <citation>Bakker AJ, Boerma EC, Keidel H, Kingma P, van der Voort PH. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med. 2006;44(8):962-6.</citation>
    <PMID>16879061</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukuda T, Toyoshima S, Nakashima Y, Koshitani O, Kawaguchi Y, Momii A. Tolerable infusion rate of citrate based on clinical signs and the electrocardiogram in conscious dogs. Clin Nutr. 2006 Dec;25(6):984-93. Epub 2006 May 15.</citation>
    <PMID>16698131</PMID>
  </results_reference>
  <results_reference>
    <citation>Forsythe RM, Wessel CB, Billiar TR, Angus DC, Rosengart MR. Parenteral calcium for intensive care unit patients. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006163. doi: 10.1002/14651858.CD006163.pub2. Review.</citation>
    <PMID>18843706</PMID>
  </results_reference>
  <results_reference>
    <citation>Pozzato M. [Citrate: an additional resource for anticoagulation in continuous replacement therapy]. G Ital Nefrol. 2012 Jan-Feb;29(1):20-6. Italian.</citation>
    <PMID>22388902</PMID>
  </results_reference>
  <results_reference>
    <citation>Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, Wang P, Li L, Jing R, Zhao L, Sun S. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med. 2015 Dec;41(12):2098-110.</citation>
    <PMID>26482411</PMID>
  </results_reference>
  <results_reference>
    <citation>Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004 Feb;30(2):260-265. doi: 10.1007/s00134-003-2047-x. Epub 2003 Nov 5.</citation>
    <PMID>14600809</PMID>
  </results_reference>
  <results_reference>
    <citation>Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant. 2011 Jan;26(1):232-9. doi: 10.1093/ndt/gfq575. Epub 2010 Sep 27.</citation>
    <PMID>20876598</PMID>
  </results_reference>
  <results_reference>
    <citation>Mariano F, Bergamo D, Gangemi EN, Hollo' Z, Stella M, Triolo G. Citrate anticoagulation for continuous renal replacement therapy in critically ill patients: success and limits. Int J Nephrol. 2011;2011:748320. doi: 10.4061/2011/748320. Epub 2011 Mar 16.</citation>
    <PMID>21603110</PMID>
  </results_reference>
  <results_reference>
    <citation>Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol. 2006 Jan;1(1):43-51. Epub 2005 Oct 26.</citation>
    <PMID>17699189</PMID>
  </results_reference>
  <results_reference>
    <citation>Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med. 2002 Oct;28(10):1419-25. Epub 2002 Sep 6.</citation>
    <PMID>12373466</PMID>
  </results_reference>
  <results_reference>
    <citation>Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009 Feb;37(2):545-52. doi: 10.1097/CCM.0b013e3181953c5e.</citation>
    <PMID>19114912</PMID>
  </results_reference>
  <results_reference>
    <citation>Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate? Crit Care. 2011 Jan 24;15(1):202. doi: 10.1186/cc9358. Review.</citation>
    <PMID>21345279</PMID>
  </results_reference>
  <results_reference>
    <citation>Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999 May;55(5):1991-7.</citation>
    <PMID>10231464</PMID>
  </results_reference>
  <results_reference>
    <citation>Cassina T, Mauri R, Engeler A, Giannini O. Continuous veno-venous hemofiltration with regional citrate anticoagulation: a four-year single-center experience. Int J Artif Organs. 2008 Nov;31(11):937-43.</citation>
    <PMID>19089795</PMID>
  </results_reference>
  <results_reference>
    <citation>Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int. 2001 Jul;60(1):370-4.</citation>
    <PMID>11422774</PMID>
  </results_reference>
  <results_reference>
    <citation>Dorval M, Madore F, Courteau S, Leblanc M. A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration. Intensive Care Med. 2003 Jul;29(7):1186-9. Epub 2003 May 22.</citation>
    <PMID>12761615</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitchell A, Daul AE, Beiderlinden M, Schäfers RF, Heemann U, Kribben A, Peters J, Philipp T, Wenzel RR. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol. 2003 Feb;59(2):106-14.</citation>
    <PMID>12608553</PMID>
  </results_reference>
  <results_reference>
    <citation>Buturovic-Ponikvar J, Gubensek J, Ponikvar R. Citrate anticoagulation for postdilutional online hemodiafiltration with calcium-containing dialysate and infusate: significant clotting in the venous bubble trap. Int J Artif Organs. 2008 Apr;31(4):323-8.</citation>
    <PMID>18432588</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang Y, Zhang P, Cui Y, Lang X, Yuan J, Jiang H, Lei W, Lv R, Zhu Y, Lai E, Chen J. Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury. Crit Care. 2013 Sep 19;17(5):R205. doi: 10.1186/cc12900.</citation>
    <PMID>24050634</PMID>
  </results_reference>
  <results_reference>
    <citation>Demirjian S, Teo BW, Guzman JA, Heyka RJ, Paganini EP, Fissell WH, Schold JD, Schreiber MJ. Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant. 2011 Nov;26(11):3508-14. doi: 10.1093/ndt/gfr075. Epub 2011 Mar 7.</citation>
    <PMID>21382993</PMID>
  </results_reference>
  <results_reference>
    <citation>Pistolesi V, Zeppilli L, Polistena F, Sacco MI, Pierucci A, Tritapepe L, Regolisti G, Fiaccadori E, Morabito S. Preventing Continuous Renal Replacement Therapy-Induced Hypophosphatemia: An Extended Clinical Experience with a Phosphate-Containing Solution in the Setting of Regional Citrate Anticoagulation. Blood Purif. 2017;44(1):8-15. doi: 10.1159/000453443. Epub 2017 Feb 21.</citation>
    <PMID>28219057</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Parma</investigator_affiliation>
    <investigator_full_name>Enrico Fiaccadori</investigator_full_name>
    <investigator_title>University Professor</investigator_title>
  </responsible_party>
  <keyword>Acute kidney injury</keyword>
  <keyword>Regional citrate anticoagulation</keyword>
  <keyword>Continuous renal replacement therapy</keyword>
  <keyword>Prolonged intermittent renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

